Biotech startup Eyestem secured $6.4 million in its Series A led by Biological E. Ltd and others

August 8, 2022

, By Sarika Parmar

Share via:

Biotech startup Eyestem secured $6.4 million in its Series A led by Biological E. Ltd, Alkem, NATCO, Anurag Bagaria and Karan Bagaria from Kemwell Biopharma where existing investors–Endiya Partners and Kotak Private Equity also participated.

Eyestem plans to use the funds to further develop its cell therapy platform and conduct early clinical trials of its patented product. Eyestem’s goal is to create a cell therapy platform to treat incurable diseases and to democratise global access to new technologies. Eyestem also stated that it has formed scientific innovation associations in India, the United Kingdom, and the United States, and that it has received grants from the Department of Biotechnology.

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We StartupNews.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It’s possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.

Previous News

upGrad raised $210 million in funds from ETS Global, Bodhi Tree and Kaizen Management Advisors

Next News

Wealthtech startup Dezerv raised $21 million in Series A led by Accel

Popular

More Like this

Biotech startup Eyestem secured $6.4 million in its Series A led by Biological E. Ltd and others

August 8, 2022

, By Sarika Parmar

Biotech startup Eyestem secured $6.4 million in its Series A led by Biological E. Ltd, Alkem, NATCO, Anurag Bagaria and Karan Bagaria from Kemwell Biopharma where existing investors–Endiya Partners and Kotak Private Equity also participated.

Eyestem plans to use the funds to further develop its cell therapy platform and conduct early clinical trials of its patented product. Eyestem’s goal is to create a cell therapy platform to treat incurable diseases and to democratise global access to new technologies. Eyestem also stated that it has formed scientific innovation associations in India, the United Kingdom, and the United States, and that it has received grants from the Department of Biotechnology.

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We StartupNews.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It’s possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.

Website Upgradation is going on for any glitch kindly connect at office@startupnews.fyi

Previous News

upGrad raised $210 million in funds from ETS Global, Bodhi Tree and Kaizen Management Advisors

Next News

Wealthtech startup Dezerv raised $21 million in Series A led by Accel

More like this

Popular

Upcoming Events

Startup Information that matters. Get in your inbox Daily!